Loading organizations...
Key people at GHS.
GHS was founded in 2002 by George Howard (Founder).
Global Health Strategies (GHS) is a consulting firm based in New York that provides advocacy, communications, and policy analysis services to advance health and development initiatives on a global scale. The organization focuses on mobilizing financial resources and building political will to address critical systemic issues, including infectious disease management, medical research and development, climate change impacts, and family planning access. Operating through an extensive international network, the firm maintains operational offices across six major global regions, specifically spanning the United States, Latin America, India, China, Africa, and Europe. The consultancy delivers strategic public health campaigns and enables policy innovations for a diverse institutional client base encompassing international philanthropies, multinational organizations, nongovernmental organizations, private industry leaders, and various sovereign government agencies. Global Health Strategies was officially established in 2002 by its founders David Gold and Victor Zonana.
GHS was founded in 2002 by George Howard (Founder).
GHS Investments, LLC is a private investment firm specializing in providing equity financing to small-cap public companies, particularly penny stock issuers, through convertible notes and funding solutions for growth.[1][3] Founded in 2015 (with operations noted from 2017), it operates from Jericho, New York, with a focus on high-potential small-cap firms, having participated in funding rounds totaling around $10 million across deals like PIPE investments.[1][3][4] The firm lacks a publicly stated mission or philosophy beyond facilitating capital access, but its activities center on sectors like healthcare and emerging tech, such as investments in Cardiff Lexington (healthcare holding) and SunHydrogen (hydrogen tech).[1][4]
Its impact on the startup ecosystem is niche: GHS supports micro-cap public companies via high-risk debt conversions, enabling quick capital but often tied to volatile OTC markets, with a track record of 3 known investments amid regulatory scrutiny.[3][4]
GHS Investments was founded in March 2015 by Mark Grober, Sarfraz S. Hajee, and a third partner (Schissler), who jointly owned and managed the firm using their personal capital.[3] Grober serves as a key principal, with the firm headquartered in Jericho, New York (also linked to Las Vegas addresses).[1][2][4] The core idea emerged from providing equity financing to small-cap public companies, evolving to include cold-calling OTC issuers (2017-2018) and note conversions sold into public markets.[3]
Early traction involved deals like a $10 million equity line and investments in penny stocks, but pivotal moments include SEC administrative proceedings in 2024, alleging unregistered broker-dealer activities across 23 issuers, generating millions in profits through discounted share sales.[1][3]
GHS rides the trend of micro-cap financing in speculative sectors like clean energy (SunHydrogen) and healthcare (Cardiff Lexington), where public listings offer quick capital amid illiquid private markets.[4] Timing aligns with post-2020 small-cap volatility, fueled by retail trading and OTC accessibility, though regulatory pressures (e.g., SEC 2024 action) highlight risks in penny stock ecosystems.[3]
Market forces favoring GHS include demand from growth-hungry small publics unable to access traditional VC/banks, influencing the ecosystem by enabling survival for niche players but amplifying dilution and volatility for shareholders.[1][3]
GHS's niche in high-risk small-cap funding persists, but post-SEC scrutiny (2024), expect tighter compliance, potential broker-dealer registration, or pivot to structured debt.[3] Trends like rising interest rates and OTC reforms could shrink opportunities, while green tech demand might boost similar deals.
Its influence may evolve toward advisory roles or selective PIPEs, distinguishing legitimate funders from past practices—watch for founder moves amid ongoing oversight. This positions GHS as a cautionary tale in micro-cap investing, underscoring the fine line between growth capital and regulatory risk.[3]
Key people at GHS.
